Related Experiment Video

Updated: Aug 7, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Reduction of left ventricular hypertrophy in children undergoing hemodialysis

Tim Ulinski1, Julie Genty, Christine Viau

  • 1Department of Pediatric Nephrology, Hôpital Armand Trousseau, 26 Av. du Docteur Netter, 75571 Paris, France. tim.ulinski@trs.aphp.fr

Pediatric Nephrology (Berlin, Germany)
|July 20, 2006
PubMed

Insights

Left ventricular hypertrophy (LVH) is common in children with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Controlling blood pressure and extracellular volume helps reduce LVH in these young patients.

Area of Science:

  • Pediatric Nephrology
  • Cardiovascular Health in ESRD
  • Renal Replacement Therapy

Background:

  • Left ventricular hypertrophy (LVH) significantly increases cardiovascular risk in adults with end-stage renal disease (ESRD).
  • Pediatric ESRD patients undergoing hemodialysis (HD) often exhibit elevated left ventricular mass (LVM).

Purpose of the Study:

  • To investigate the prevalence and progression of LVH in pediatric ESRD patients treated with HD.
  • To identify factors associated with LVM changes during HD treatment in children.

Main Methods:

  • Retrospective analysis of 17 pediatric patients (median age 11 years) undergoing HD.
  • Measurement of left ventricular mass index (LVMi) at the start of HD and during follow-up.
  • Monitoring of blood pressure (BP) and plasma protein levels.

Main Results:

  • Initial LVMi was significantly reduced from 54.8+/-4.5 g/m2.7 to 36.2+/-2.6 g/m2.7 at follow-up (P<0.0001).
  • Systolic and diastolic blood pressure decreased significantly (P<0.0001).
  • Hemoglobin levels increased by +2.8 g/dL (P<0.0001).
  • Only BP and plasma protein levels at HD onset correlated with LVM.

Conclusions:

  • Elevated LVM is a frequent characteristic of pediatric ESRD patients on HD.
  • Normalization of blood pressure and reduction of extracellular volume are crucial for managing LVH in children undergoing HD.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...